Nancy E Lane, MD

Dr. Nancy E. Lane is an Endowed Professor of Medicine and Rheumatology


Dr. Nancy E. Lane is an Endowed Professor of Medicine and Rheumatology and Director of the Musculoskeletal Diseases and Aging Research Group at University of California at Davis School of Medicine. Dr. Lane received her medical degree at the University of California at San Francisco, performed her Internal Medicine Residency at the Mt. Zion/University of California at San Francisco campus and performed her Rheumatology subspecialty fellowship at Stanford University Medical Center. Dr. Lane was a faculty member in the Division of Rheumatology in the Department of Medicine at the University of California at San Francisco for 15 years and for the past 6 years has been at the University of­­ California at Davis School of Medicine in Sacramento, California.

Dr. Lane’s research focuses on both the study of musculoskeletal diseases of aging, and clinical research in the rheumatic diseases. Dr. Lane is a clinical rheumatologist who has performed translational research in osteoporosis, osteoarthritis and rheumatic diseases for over 20 years. She performed one of the initial studies of a TNF blocking agent for the treatment of rheumatoid arthritis; studies of parathyroid hormone to treat osteoporosis; the study of glucosamine and chondroitin sulfate for the treatment of painful knee OA; and studied the effect of weight-bearing exercise (running) on the development of osteoarthritis of the knee.

Dr. Lane’s expertise in bone diseases led to her seminal work testing the use of PTH to treat glucocorticoid-induced bone loss, and in osteoarthritis studies evaluating a novel analgesic agent, an inhibitor of nerve growth factor. Dr. Lane’s current research is focused on the epidemiology and genetic risk factors for osteoarthritis of the hip and knee; treatments to reverse sarcopenia in aging individuals and those with chronic inflammatory diseases; and in-depth evaluations of Magnetic Resonance Imaging to determine the development and progression of joint deterioration with knee and hip osteoarthritis.

Dr. Lane has published over 200 articles in peer-reviewed journals, over 20 book chapters and has given numerous seminal lectures on rheumatologic issues nationally and internationally; she was a co-editor for Arthritis & Rheumatism and is currently an associate editor for both Seminars in Rheumatology and the journal Rheumatology.

Dr. Lane is also active in national subspecialty societies including the American College of Rheumatology, having participated in committee work and educational activities; the American Society of Bone and Mineral Research in which she is currently a member of the Council; a member of the Osteoarthritis and Cartilage society (OARSI); and is past president of the Executive Board of the United States Bone and Joint Decade (2006-2008).


  1. Lane NE, Schnitzer TJ, Birbara CA, Masoud Mokhtarani, Shelton DL, Smith MD, Brown MT. Efficacy and safety of anti-nerve growth antibody, tenezumab in the treatment of moderate to severe pain due to osteoarthritis of the knee. N Engl J Med 363:1521-1531, 2010
  2. Lane NE. Vitamin D and Systemic Lupus Erythematous: Bones, Muscles, Joints. Current Rheumatology Reports 2010 Aug;12(4):259-63.
  3. Lane NE, Yao W. Glucocorticoid induced bone fragility: new insights. Proceedings of the New York Academy of Sciences, Mar;1192(1):81-3, 2010
  4. Lane NE. Osteoarthritis of the hip, clinical review, New Engl J Med Oct 4;357(14):1413-1421, 2007
  5. Lane NE. Long-term effects of treatment with alendronate for patients with osteoporosis. Nat Cln Pract Rheumatol 2007 agu;3(8):426-7.
Bookmark and Share